FINWIRES · TerminalLIVE
FINWIRES

Starbucks Q2 Sales, Earnings Upside Seen on Improving US Trends, UBS Says

By

Starbucks' (SBUX) upcoming fiscal Q2 results are expected to show progress on initiatives to support its accelerating sales trends, with likely upside to sales, margins and earnings, UBS Securities said in a Tuesday note.

The company is scheduled to report its Q2 results on April 28.

UBS said it now expects Q2 North America same-store sales of 6%, up from 4% previously, compared with the consensus of 4%, and forecasts ticket growth of 1% and transaction growth of 5%.

The brokerage said sales are improving with traction against strategic plans including menu innovation, new bakery lineup, continued benefits from the Green Apron Service and operational improvements, adding that it expects North America same-store sales of 5% in fiscal Q3 and 4.7% in fiscal 2026.

Additionally, the investment firm said it is modeling adjusted operating margins of 8.6% for fiscal Q2, versus the consensus of 8.3%, aided by easing inflation, lapping investments and cost savings plans. For fiscal 2026, UBS expects operating margins of 10.6%.

UBS has a neutral rating on the company's stock with a $100 price target.

Price: $97.35, Change: $-1.60, Percent Change: -1.62%

Related Articles

Wire

IDP Education to Introduce Malaysia as Study Destination

IDP Education (ASX:IEL) expanded its range of study destinations by supporting students to study in Malaysia, according to a Tuesday statement.The company cited changing student preferences as a reason for the move, with growing demand for new destinations offering strong education quality, career outcomes, and affordable study options.The initial rollout will focus on a select number of markets as part of a phased pilot.IDP Education's shares declined 1% in recent trading on Tuesday.

ASX:IEL
Wire

Infratil Says Moody's Assigns CDC Data Centers 'Baa2' Rating, Stable Outlook

Infratil (NZE:IFT, ASX:IFT) said Moody's Ratings has assigned CDC Data Centers Australia its first public investment grade credit rating of "Baa2" with a stable outlook, according to Tuesday filings with the Australian and New Zealand bourses.The rating reflects CDC's strong financial position, stable long-term contracted revenues, and exceptionally long lease durations averaging 28.4 years, per the filing.The rating will enable CDC to improve access to capital markets, supporting further large-scale infrastructure development driven by rising demand from government, hyperscale cloud providers, and critical industries, the filing added.The company's Kiwi shares shed 1% in recent Tuesday trade.

ASX:IFTNZE:IFT
Wire

Spruce Biosciences Begins Public Offering of Stock, Prefunded Warrants; Shares Fall After Hours

Spruce Biosciences (SPRB) said late Monday it commenced an underwritten public offering of common shares or related prefunded warrants.The company expects to grant underwriters a 30-day option to buy up to 15% more stock at the public offering price, less underwriting discounts and commissions.The offering is subject to market and other conditions, Spruce said.Spruce shares fell 13% in after-hours trading.

$SPRB